Analysts Set Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Target Price at $4.50

Key Points

• Milestone Pharmaceuticals has received an average consensus recommendation of "Hold" from five brokerages, with three holding and two buying ratings.
• The average twelve-month price target for Milestone Pharmaceuticals is $4.50, with Wells Fargo setting a target of $4.00 and HC Wainwright at $5.00.
• The company recently reported earnings of ($0.20) EPS for the quarter, missing the consensus estimate of ($0.18).

Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) have received an average recommendation of "Hold" from the five ratings firms that are presently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $4.50.

Several equities analysts have recently issued reports on the company. HC Wainwright upgraded Milestone Pharmaceuticals to a "buy" rating and set a $5.00 price target on the stock in a research note on Thursday, June 5th. Wells Fargo & Company assumed coverage on Milestone Pharmaceuticals in a research note on Thursday, September 11th. They issued an "overweight" rating and a $4.00 price target on the stock.

Institutional Investors Weigh In On Milestone Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Toronto Dominion Bank acquired a new position in shares of Milestone Pharmaceuticals in the 4th quarter valued at about $1,770,000. Northern Trust Corp grew its holdings in shares of Milestone Pharmaceuticals by 112.6% in the fourth quarter. Northern Trust Corp now owns 58,108 shares of the company's stock valued at $137,000 after acquiring an additional 30,772 shares in the last quarter. Propel Bio Management LLC bought a new position in Milestone Pharmaceuticals during the first quarter valued at $1,161,000. Walleye Capital LLC bought a new position in Milestone Pharmaceuticals during the first quarter valued at $74,000. Finally, XTX Topco Ltd lifted its position in shares of Milestone Pharmaceuticals by 52.7% during the first quarter. XTX Topco Ltd now owns 52,004 shares of the company's stock worth $42,000 after acquiring an additional 17,950 shares in the last quarter. Institutional investors own 86.18% of the company's stock.

Milestone Pharmaceuticals Trading Up 2.3%

NASDAQ:MIST traded up $0.05 during mid-day trading on Thursday, hitting $2.02. The company had a trading volume of 929,597 shares, compared to its average volume of 1,678,603. Milestone Pharmaceuticals has a fifty-two week low of $0.63 and a fifty-two week high of $2.75. The business's fifty day moving average is $1.70 and its two-hundred day moving average is $1.55. The company has a debt-to-equity ratio of 4.06, a quick ratio of 4.97 and a current ratio of 4.97. The firm has a market cap of $171.26 million, a P/E ratio of -2.40 and a beta of 0.60.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.02). As a group, research analysts expect that Milestone Pharmaceuticals will post -0.62 earnings per share for the current year.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.